ANAHEIM, Calif., June 16, 2017 (GLOBE NEWSWIRE) -- Gala Global, Inc. (OTC:GLAG), a publicly-traded development firm specializing in equity investments, debt financing and mergers and acquisitions in the biotechnology industry, has named Dr. Maqsood “Max” Rehman as the company’s Chief Operating Officer (COO).
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/74ff43f6-51a0-4eec-901c-32d3cb7d83a2
“We welcome Dr. Rehman as he brings with him a diverse background of working for large public and private companies in the field of genetics and the commercialization of genetically modified crops for a wide variety of uses,” said Gala Global CEO Timothy Madden.
Dr. Rehman comes to Gala Global from doing work as a global soybean breeding leader for Dow AgroSciences, Indianapolis, Ind.
Dr. Rehman will be leading Gala Global’s development team working to commercialize digital plant cloning incubators from Controlled Environment Genomics, Inc. (CEG), an Akron, Ohio-based genomics company recently acquired by Gala Global that specializes in digital plant gene sequencing, editing and cloning technologies.
CEG’s state-of-the-art genomics technology makes possible digital genome sequencing and plant cloning systems. These enable developers to digitally sequence the genomes of the most desirable plant varieties based on flavor and nutrition. As a result, the very best plant traits can be used to improve the most sought-after commercial varieties with characteristics like maximized yield and quality conducive to increased consumer demand and improved production profitability.
Dr. Rehman will also be working with GenoBreeding Inc., a division of Greengro Technologies, Inc. (OTC:GRNH), Anaheim, Calif. GenoBreeding was formed in early 2017 to direct a Greengro initiative intended to bring to the plants and herbs markets cutting-edge plant varieties through the application of modern plant breeding technologies.
Gala’s business strategy is to develop breeding tools like molecular markers to enable productive plant breeding decisions and processes that achieve top-tier plant performance in a sustainable manner.
Gala Global Development Team:
Dr. Maqsood “Max” Rehman is currently working as a global soybean breeding leader for Dow AgroSciences at Indianapolis, Ind. Previously, he worked as a soybean breeder for Monsanto Company at Oxford, Indiana. Max has Masters and PhD degrees in Plant Science from University of Idaho, U.S.A. and Post Doctorate from University of Missouri-Columbia, Missouri. He has a diversified scientific background with training, and 10 plus years of practical experience in plant breeding, quantitative and molecular genetics and cytogenetics and project management.
As global soybean breeding lead, he provides leadership to the soybean breeding organization for the successful launch of competitive soybean varieties in North America and Latin America. He develops breeding strategies and develops budgets needed to accomplish breeding goals. Max bridges gaps by bringing together stakeholders (Breeding, labs, business and commercial) and aligns breeding goals with global business goals through effective communication. His implementation of innovative ideas aligned with business and R&D creates value. Max brings efficiency within resources that lead towards a fast genetic gain in crop production. Max develops teams and provides effective and transparent communication processes to achieve deliverables.
Dr. Ajay Mahajan is the President of Clipius Technologies Inc., and is currently a tenured professor in the mechanical engineering and biomedical engineering departments at The University of Akron, in Ohio. He is currently the chair of the finance committee for the Akron BioInnovation Fund II (ABFII) for the City of Akron. He was the associate vice president for innovation for the University, and the associate dean for research in the College of Engineering until 2015.
Before coming to Akron he worked at Southern Illinois University Carbondale. He is currently a board member for the Bell Chapter of the Hawkins Foundation that advances orthopedic medicine and outcomes for patients through research and education. In the past he has worked with NASA, US DoD, US Federal Highway, as well as companies such as Timken, Caterpillar and Medtronic. He has also worked with two Formula One teams (Renault F1 and Toyota F1).
He is the co-founder and president of Clipius Technologies, a high-tech genomics device company, and serves on the boards of many organizations/companies. He has developed numerous biomedical devices and has also run numerous cadaver labs for Medtronic while testing that company’s new devices for FDA approval and marketing claims. In NE Ohio, he has been a champion for increasing/improving the technology and innovation ecosystem.
Two years ago, he served on President Barack Obama’s Advanced Manufacturing Partnership (AMP2.0) initiative at the White House.
Wilfred Hemker is an R&D scientist and entrepreneur experienced in new product development, identifying advanced technology, IP assessment, and leading partnership teams to commercialize innovative products. His successes include: commercializing IP protected products using advanced technology for the environmental, food production, new product materials for over-the-counter (OTC) dermatological and anti-microbial marketplaces.
Wil is a senior entrepreneur fellow at the University of Akron Research Foundation (UARF) commercializing new materials and technologies into environmental, food production and biomedical markets. Wil holds a BS in chemistry from Bowling Green State University and a MS in Food Science from The Ohio State University. He is very active in the food movement including ways to increase nutrition in schools, hospitals and institutions.
Timothy Madden, a serial entrepreneur, inventor and business executive, has positioned his companies as leaders in the U.S. indoor agriculture industry. His extensive knowledge of plant science, greenhouses, integrated renewable energy systems and fully automated controlled environment agriculture (CEA) technologies provides his companies with significant competitive advantages in their respective markets.
Tim’s education and experience include a degree in computer electronics from Fortis College, ten years as founder and President of Biodynamics Inc., and three years as founder and manager of On Point Hydroponics LLC, currently serving as CEO of Gala Global Inc.
As part of his early education, Tim studied the work of Dr. Rudolf Steiner, a scientist, philosopher and inventor of commercial-scale organic agriculture. Steiner published his work in 1924 to combat the rapid worldwide decline in crop nutritional value and fertility occurring in the 20th century as a result of monoculture practices and the overuse of pesticides. The science of indoor agriculture is founded on the need for crop production as a closed loop agricultural system, self-contained and self-sustaining, creating and maintaining life, free of external contaminants and the production of pollution. Tim has helped make Dr. Steiner’s vision a reality in his own work through entrepreneurship and the invention and development of proprietary controlled environment technologies operated by artificial intelligence (AI) technologies and powered by integrated renewable energy systems.
About Gala Global Inc.
Gala Global, Inc., Anaheim, Calif., is a publicly-traded startup development company specializing in equity investments, debt financing and mergers and acquisitions (M&A) in the biotech industry. Gala Global’s professional services group provides operational services and technologies that drive efficiencies in the market. Gala Global has industry-leading expertise helping companies make the most of their potential in an emerging market. Gala Global website: www.galaglobalinc.com.
About Controlled Environment Genomics, Inc.
Controlled Environment Genomics, Inc. (CEG), an Akron, Ohio based genomics company recently acquired by Gala Global Inc., specializing in digital plant gene sequencing, editing, and cloning technologies. CEG’s state-of-the-art genomics technology enables digital genome sequencing and plant cloning in fully automated turn-key solution providing the ability to digitally sequence the genomes of the most desirable plant varieties based on flavor and nutrition, so the best traits can be used to improve the most sought after commercial varieties with traits like increased yield, and quality, thus enhancing consumer demand for the product and increasing profitability.
About Greengro Technologies, Inc.
Greengro Technologies, Inc., (OTC:GRNH) is a world class provider of eco-friendly green technologies with specific domain expertise in indoor and outdoor agricultural science systems serving both the consumer and commercial farming markets. It brings together community and commerce through the growth and distribution of healthy, nutritious foods and vital medicines backed by science and technology. Customers include restaurants, community gardens, and small and large scale commercial clients. Greengro Technologies also provides design, construction and maintenance services to large grow and cultivation operations and collectives in the medical and recreational cannabis sectors. The company’s websites: www.greengrotech.com, offer regular updates including educational videos, projects updates, recipes and nutritional information, and where to find the company’s products.
About GenoBreeding , Inc.
GenoBreeding is a subsidiary of Greengro Technologies, Inc. GenoBreeding is also developing a proprietary digital genetic database that will be used as an online cloud-based library of digitally sequenced genomes and phenotypic (chemical composition) information on all existing and new plant varieties.
CEG Inc. proprietary digital plant cloning technology will enable GenoBreeding ’s geneticists to select the best plant varieties to hybridize, improving and increasing crop quality and yields, by combining the very best genetics, maximizing the variation of positive inherited characteristics in each variety.
Disclaimer: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.
Source:Gala Global, Inc.